Search company, investor...

Arbor Pharmaceuticals


Acquired | Acquired

Total Raised


About Arbor Pharmaceuticals

Arbor Pharmaceuticals is a specialty pharmaceutical company currently focused on the cardiovascular, hospital and pediatric markets. On August 24th, 2021, Arbor Pharmaceuticals was acquired by Azurity Pharmaceuticals. Terms of the transaction were not disclosed.

Headquarters Location

6 Concourse Parkway Suite 1800

Atlanta, Georgia, 30328,

United States


Missing: Arbor Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Arbor Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Arbor Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Arbor Pharmaceuticals is included in 2 Expert Collections, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.


Sleep Health & Wellness

804 items

These companies aim to assess or improve the quantity/quality of sleep, or use sleep data in the monitoring or diagnosis of other health conditions.

Arbor Pharmaceuticals Patents

Arbor Pharmaceuticals has filed 39 patents.

The 3 most popular patent topics include:

  • Prodrugs
  • Calcium channel blockers
  • Hypertension
patents chart

Application Date

Grant Date


Related Topics




Vascular diseases, Hypertension, Calcium channel blockers, Diseases of the aorta, Neurotrauma


Application Date


Grant Date



Related Topics

Vascular diseases, Hypertension, Calcium channel blockers, Diseases of the aorta, Neurotrauma



Latest Arbor Pharmaceuticals News

Precocious Puberty Treatment Market is projected to reach US$ 3,650.66 million by 2033

Mar 21, 2023

Precocious Puberty Treatment Market is projected to reach US$ 3,650.66 million by 2033 The global  precocious puberty treatment market  is anticipated to attain an impressive valuation of US$ 1,716.43 million in 2023 and is projected to reach US$ 3,650.66 million by 2033, trailing a CAGR of 7.8% during the forecast period. The focus of key industry players on getting product approval from regulatory authorities such as United States Food and Drug Administration (FDA), which is expected to propel the market growth during the forecast period. For example, in May 2020, Tolmar Pharmaceuticals, Inc., a pharmaceutical company, received authorization and approval for its New Drug Application from the Unites states FDA for FENSOLVI (leuprolide acetate) for injectable suspension for the treatment of pediatric patients aged two years and older with precocious puberty. This is projected to propel market growth during the forecast period. Get Latest Sample Copy@ Likewise, these players are focusing on a number of inorganic strategies such as partnerships, mergers, and agreements, which is expected to drive the precocious puberty market growth during the forecast period. For example, in January 2016, Debiopharm International SA (Debiopharm) which is a part of Debiopharm Group, made an agreement for exclusive distribution agreement with Arbor Pharmaceuticals, a pharmaceutical company, for the commercialization and promotion of triptorelin 22.5 mg for Central precocious puberty treatment. On the other hand, surging research and development activities in triptorelin for applications in several therapeutic indications, by private manufacturers and research organizations is fuelling growth of precocious puberty treatment market. Moreover, the higher efficacy and tolerability of triptorelin in the suppression of gonadotropin secretion in prostate cancer and precocious puberty is surging the adoption of triptorelin in the market which is anticipated to benefit the market of precocious puberty. Ask An Analyst @ Also, the engagement by key players in expanding their product portfolio in several geographical areas is expected to aid market growth. For example, in October 2017, Arbor Pharmaceuticals, LLC and Debiopharm International SA commercialized availability of Triptodur (triptorelin), in the United States for the treatment of pediatric patients two years and older diagnosed with Precocious Puberty. Furthermore, reimbursement for the treatment of precocious puberty is provided through Medicaid, which is estimated to offer lucrative growth prospects for the global precocious puberty market during the forecast period. Key Takeaways from the Market Study North America is expected to dominate the industry while reaching market share of around 46.7% by end of the forecast period. The market in East Asia is projected to account for 25% market share by end of the projected period. By drug class, ‘triptorelin’ is projected to account for 62% market share by end of the forecast period. Hospitals are expected to dominate the market by distribution channel, with a market share of 58% by 2033. “Increasing rate of product approvals, surging growth in mergers and acquisitions between companies, and development of new drugs will increase the product demand for treatment of precocious puberty,” comments an FMI analyst. Competitive Landscape The precocious puberty treatment market is extremely competitive and consists of various key market players. These players are developing novel delivery systems for treating precocious puberty. This is anticipated to fuel precocious puberty treatment market. The key players in this market are: Teva Pharmaceutical Industries Ltd, AbbVie Inc., Arbor Pharmaceuticals, LLC, Pfizer Inc, Tolmar Pharmaceuticals, Inc., Endo International plc, Ipsen Pharma, Debiopharm Group, Sun Pharmaceutical Industries Limited, Sanofi Key industry players are inclined on adoption of inorganic growth strategies like acquisition, partnerships, and collaboration in order to bolster their product portfolio. This is expected to propel the global precocious puberty treatment market. In June, 2020, Ipsen Pharma undergone strategic partnership with Debiopharm for Decapeptyl (triptorelin) for another 15 years. Decapeptyl (triptorelin) is used for treating central precocious puberty in children. This strategic merger helped the company to maintain a continuous product access to patients. In March 2022, Accord BioPharma, the United States special division of Intas Pharmaceuticals, Ltd. declared the United States launch of CAMCEVI (leuprolide) 42mg injection emulsion for the treatment of progressive prostate cancer in adults.In February 2022, BDR Pharmaceuticals revealed its brand ENZALUTAMIDE, an antiandrogen in 160mg with brand name BDENZA for treatment of Prostate Cancer patients. In January 2019, Debiopharm group informed about an agreement with Allergan to begin a transition process for Trelstar (Triptorelin pamoate) intended to lead to new licensees taking over the commercialization of Trelstar in the United States and Canada and the termination of Allergan’s partnership with Debiopharm for strategic reasons. More Valuable Insights Available Future Market Insights offers an unbiased analysis of the global Precocious puberty treatment market, providing historical data for 2018-2022 and forecast statistics from 2023-2033. To understand opportunities in the precocious puberty treatment market the market is segmented on the basis of drug class ( Leuprorelin, Histrelin, Triptorelin, Nafarelin) By distribution channel (Hospital pharmacies, retail pharmacies, online pharmacies (By region (North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East and Africa). Key Segments Profiled in the Precocious Puberty Treatment Industry Survey By Drug Class:

Arbor Pharmaceuticals Frequently Asked Questions (FAQ)

  • Where is Arbor Pharmaceuticals's headquarters?

    Arbor Pharmaceuticals's headquarters is located at 6 Concourse Parkway, Atlanta.

  • What is Arbor Pharmaceuticals's latest funding round?

    Arbor Pharmaceuticals's latest funding round is Acquired.

  • How much did Arbor Pharmaceuticals raise?

    Arbor Pharmaceuticals raised a total of $34.8M.

  • Who are the investors of Arbor Pharmaceuticals?

    Investors of Arbor Pharmaceuticals include Azurity Pharmaceuticals, KKR, ARCH Healthcare Fund, Signet Healthcare Partners and JW Asset Management.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.